Foghorn Therapeutics (FHTX)

Executive Summary

Foghorn Therapeutics (NASDAQ: FHTX) is a clinical-stage biopharmaceutical company pioneering precision medicines targeting the chromatin regulatory system, a key driver of gene expression in cancer. Its lead candidate, FHD-286, is a potent inhibitor of the BRG1/BRM ATPase subunits of the BAF chromatin remodeling complex, currently in Phase 1 trials for acute myeloid leukemia (AML) and other hematologic malignancies. The company is also evaluating FHD-286 in combination with decitabine and venetoclax (NCT07283094) and with low-dose cytarabine (NCT04891757). Although earlier Phase 1 studies in metastatic uveal melanoma and synovial sarcoma were terminated, Foghorn continues to advance its core hematology program. The company maintains a strategic collaboration with Loxo Oncology at Lilly, which provides validation and potential future milestones. With a market cap of approximately $245 million, Foghorn represents an early-stage investment opportunity tied to the emerging field of chromatin remodelling therapeutics.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data update for FHD-286 combination regimens in AML55% success
• H1 2027Initiation of potential registrational cohort or expansion study for FHD-28640% success
• TBDNew pipeline program or proof-of-concept data from chromatin platform30% success